Affiliation:
1. Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA
2. Indiana University Center for Health Innovation and Implementation Science, School of Medicine, Indianapolis, IN, USA
Abstract
Background: Early detection of Alzheimer’s disease (AD) is a key component for the success of the recently approved lecanemab and aducanumab. Patients with neuroinflammation-related conditions are associated with a higher risk for developing AD. Objective: Investigate the incidence of AD among patients with neuroinflammation-related conditions including epilepsy, hemorrhage stroke, multiple sclerosis (MS), and traumatic brain injury (TBI). Methods: We used Optum’s de-identified Clinformatics Data Mart Database (CDM). We derived covariate-matched cohorts including patients with neuroinflammation-related conditions and controls without the corresponding condition. The matched cohorts were: 1) patients with epilepsy and controls (N = 67,825 matched pairs); 2) patients with hemorrhage stroke and controls (N = 81,510 matched pairs); 3) patients with MS and controls (N = 9,853 matched pairs); and 4) patients TBI and controls (N = 104,637 matched pairs). We used the Cox model to investigate the associations between neuroinflammation-related conditions and AD. Results: We identified that epilepsy, hemorrhage stroke, and TBI were associated with increased risks of AD in both males and females (hazard ratios [HRs]≥1.74, p < 0.001), as well as in gender- and race-conscious subpopulations (HRs≥1.64, p < 0.001). We identified that MS was associated with increased risks of AD in both males and females (HRs≥1.47, p≤0.004), while gender- and race-conscious subgroup analysis shown mixed associations. Conclusions: Patients with epilepsy, hemorrhage stroke, MS, and/or TBI are associated with a higher risk of developing AD. More attention on cognitive status should be given to older patients with these conditions.
Reference47 articles.
1. (2022) 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 18, 700–789.
2. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease;Budd Haeberlein;J Prev Alzheimers Dis,2022
3. Lecanemab in early Alzheimer’s disease.;van Dyck;N Engl J Med,2022
4. Aducanumab: Appropriate use recommendations.;Cummings;J Prev Alzheimers Dis,2021
5. Aducanumab: Appropriate use recommendations update;Cummings;J Prev Alzheimers Dis,2022